Tectonic Therapeutic Joins Russell 3000® Index

Rhea-AI Summary

Tectonic Therapeutic (NASDAQ: TECX), a clinical stage biotech company specializing in therapeutic proteins and antibodies for GPCR modulation, has been added to the Russell 3000® Index following the 2025 Russell US Indexes annual reconstitution, effective June 30, 2025.

The inclusion automatically places Tectonic in either the Russell 1000® Index or Russell 2000® Index, along with corresponding growth and value style indexes. The Russell 3000® Index membership, which is determined by market capitalization rankings and style attributes, will remain in place for one year.

Positive

• Inclusion in the Russell 3000® Index increases visibility and exposure to institutional investors
• Automatic inclusion in additional Russell indexes provides broader market exposure

Negative

• None.

WATERTOWN, Mass., June 30, 2025 (GLOBE NEWSWIRE) -- Tectonic Therapeutic, Inc. (NASDAQ: TECX) (“Tectonic”), a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (GPCRs), today announced that it has been added to the broad-market Russell 3000^® Index. Tectonic’s addition follows the conclusion of the 2025 Russell US Indexes annual reconstitution and is effective after the open of US equity markets on Monday, June 30, 2025.

The annual reconstitution of the Russell US indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000^® Index, which remains in place for one year, results in automatic inclusion in the large-cap Russell 1000® Index or small-cap Russell 2000® Index as well as the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes.

For more information on the Russell 3000^® Index and the Russell indexes reconstitution, go to the “Russell Reconstitution” section on the FTSE Russell website.

About Tectonic
Tectonic Therapeutic is a clinical-stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Leveraging its proprietary technology platform called GEODe™ (GPCRs Engineered for Optimal Discovery), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in Watertown, Massachusetts. For more information, please visit www.tectonictx.com and follow us on LinkedIn.

Contacts:

Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Media:
Kathryn Morris
The Yates Network
kathryn@theyatesnetwork.com
(914) 204-6412

FAQ

When will Tectonic Therapeutic (NASDAQ: TECX) join the Russell 3000® Index?

Tectonic Therapeutic will join the Russell 3000® Index effective after the open of US equity markets on Monday, June 30, 2025.

What does Russell 3000® Index inclusion mean for Tectonic Therapeutic?

Inclusion means automatic membership in either the Russell 1000® or Russell 2000® Index, plus corresponding growth and value style indexes, lasting for one year.

What is Tectonic Therapeutic's (TECX) main business focus?

Tectonic is a clinical stage biotechnology company focused on discovering and developing therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs).

How are companies selected for the Russell 3000® Index?

Companies are selected based on market capitalization rankings of the 4,000 largest US stocks as of April 30, along with style attributes determined by FTSE Russell.